Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, ...

GRI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of the small molecule RAR ...

The decision was influenced by the analysis involving 160mg and 320mg doses of the therapy, indicating an unfavourable ...

A trial using PET scans to test the anti-inflammatory drug PIPE-791 finished enrolling healthy volunteers and patients with ...

The University of Texas at Tyler was awarded a $219,000 grant to help fund a professor’s pulmonary fibrosis treatment project ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...